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imaging device for treatment planning. This method will be 
used for palliative patients with painful vertebral metastases. 
Our challenge is to determine the impaired vertebrae on the 
CBCT. These vertebrae are known in advance from the 
diagnostic scan. The CBCT only covers 16 cm, which makes it 
impossible to count the vertebrae for cases in which either L5 
or C1 is not shown.  
Materials and Methods: A Varian iX accelerator with OBI is 
used to make the CBCT. Treatment planning is performed 
with EclipseTM v10.0 (Varian). We use a homemade bottom 
plate on the table which contains lead BB's every 10cm. 
These marker positions are distinguishable by the number of 
BB's. We take a kV-image including either C1 or L5 and note 
at which vertebra the first marker position is projected. 
Then, we shift the table, take another image with both the 
first and a second marker position, and note at which 
vertebra this second marker position is projected. We repeat 
this procedure until the impaired vertebrae and the marker 
closest to these vertebrae is imaged. We perform the CBCT 
with the center at these impaired vertebrae. The CBCT is 
used for treatment planning. QA of the calculation shows that 
the dose calculation on the CBCT scan corresponds with the 
calculation on the CT scan with deviations up to 1.5% for a 
6MV beam, calculated with the AAA algorithm. The patient is 
treated the same day without a regular planning-CT. 
Results: We have tested the imaging procedure on an 
anthropomorphous phantom. Figure 1 shows the kV-images 
when counting starts at L5. The red arrow and the blue arrow 
each denote the same patient position on the couch. In 
between the images the couch has been shifted 
approximately 10 cm.  
 
Fig 1 
 
Conclusions: We intend to perform the treatment of 
vertebral metastases for palliative patients close to their 
home in a one-stop procedure. We use an imaging procedure 
based on kV-imaging with the aid of a homemade bottom 
plate, followed by a CBCT. The CBCT is used for treatment 
planning. The procedure has been tested on an 
anthropomorphous phantom and will be used clinically from 
January 2015.  
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Purpose/Objective: Our goal was to optimize the bladder 
volume on the planning CT scan according to the department 
bladder filling protocol, for patients referred for pelvic 
radiotherapy. 
Our hypothesis was, the ultrasound bladder scanner could 
define the bladder volume, with the accuracy 100ml, 
compared to the planning CT scan. We also wanted to 
evaluate the bladder volume changes according to time. 
Materials and Methods: All patients were instructed to 
comply with a bladder filling protocol before planning CT 
scan. Optimal filling was considered to be 150-300 ml. 
A radiographer measured the bladder volumes three times, 
according to the list below.  
1. ultrasound bladder scan before patient set up, average of 
3 measurements 
2. measurement on planning CT scan, using bladder outline 
contours  
3. ultrasound bladder scan after planning CT scan, average of 
3 measurements 
All scans were time registered. If the bladder volume in scan 
1 was >300 ml we asked the patients to empty the excess 
bladder volume corresponding to measurements in cups. 
Afterwards we restarted the measuring. These reported 
volumes are all after emptying. If the bladder volume in scan 
1 was 150-300 ml or < 150 ml, we did not interfere. 
Results: We collected data from 33 patients, with the 
following cancer diagnoses: Anal, prostate, Rectal and 
gynecological. All patients had scan 1 and scan 2 and 30 
patients also had scan 3. All patients who were asked to 
empty excess bladder volume could cooperate to the 
instructions. 
The median time span between scan 1 and scan 2 was 12 min 
(range 6-45 minutes) and the median time span between scan 
1 and scan 3 was 17 min (range 10-45 min). The median 
bladder volume in scan1 was 103 ml (range 24-264 ml), in 
scan 2: 179 ml (range 61-400 ml) and in scan 3: 181ml (range 
16-312 ml) 
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The reason why scan 3 correlates better to scan 2 is due to 
the shorter timespan between scan 2 and scan 3 compared to 
the timespan between scan 1 and scan 2. In this timespan the 
patients continuously produced urine. 
The bladder scanner measured the fluid volume inside the 
bladder and the bladder volume on the planning CT included 
the bladder wall, which of course introduce a systematic 
difference between the 2 measurements 
The overall changes in bladder volume over time revealed 
that the ultrasound bladder scan should be performed before 
15-20 minutes of the planning CT. Within this timeframe the 
bladder volume would not differ more than 150 ml 
Conclusions: The data shows, that we can rely on, and use 
the measures from the ultrasound bladder scan. Therefore, 
the bladder scan is a non-ionizing god tool, to optimize 
bladder volume in the everyday work flow. 
Our futures plans involve monitoring of inter observer 
differences in bladder volume measurements and how to 
incorporate our findings in the treatment executive process. 
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Purpose/Objective: Oral cavity (OC) is an important organ at 
risk (OAR) to keep in mind when planning radiotherapy 
treatment in locally advanced head and neck cancer patients. 
The quality of life in these patients can be diminished 
because of the mucositis profile, reducing the tolerance and 
efficacy of the therapy. Lowering the D mean and D max 
constraints to the OC without compromise the prescribe dose 
to the PTV can be achieved helping to decrease the risk of 
sever mucositis (Figure 1). There are no consensuses that 
demonstrate a better way of contour the OC as OAR. The 
objective of this study is to investigate how the method we 
used to contour the OC influences on dosimetry without 
compromising the treatment compliance and reduces the risk 
of severe mucositis. 
Figure 1. Oropharyngeal mucositis secondary to chemo-
radiotherapy without contouring OC as OAR. 
 
 
 
Materials and Methods: Nineteen patients with locally 
advance head and neck cancer treated with Intensity 
Modulated Radiotherapy (IMRT) techniques were analysed in 
this study. Treatment was designed according to 
international recommendations utilising IMRT technique with 
7 fields and dynamic multileaf collimator, delivering dose 
between 66 and 70 Gy to the PTV. The Monaco treatment 
planning system with Monte Carlo algorithm was used. The 
same physician made the contouring of the PTV volume and 
the OC. The oral cavity included: hard palate mucosa, floor 
of the mouth, orbicular muscle and lips, upper and lower 
teeth and gingiva, oral vestibule and the ventral 2/3 portion 
of the tongue.Patients were followed weekly by the physician 
recording and classifying the grade of mucositis in two 
groups, group A: asymptomatic or mild ulcers and group B: 
severe ulcers or mayor bleeding pseudo membrane. Oral 
cavity D mean, D max, V50Gy, V45Gy, V40Gy, V35Gy, V30Gy, 
V25Gy and V20Gy were recorded and compared. We used a 
standard statistical analysis to describe the D mean, D max 
and volumes with the grade of mucositis appearance. We 
have compared our results with similar published series. 
Results: The PTV median prescribed dose was 67Gy (range: 
66-70Gy) without losing tighter values of D max: 38.3Gy 
(range: 32-52) and D mean: 18Gy (range: 10-26Gy). In the 
group A, 15 patients (78.9%) were assessed with mucositis 
toxicity grade ≤2 and in-group B, only 4 patients (21%) 
reached a mucositis toxicity grade ≥3 with no severe 
complications. In the 19 cases the OC volumes mean was 
96.4cc accomplishing lower doses in the oral cavity has an 
organ at risk. We also evaluated the V20, V25, V30, V45 and 
V50 of the OC. 
(Table 1) 
Age (years) 57 (range: 45-84) 
Gender 
Male 
Female 
12 
7 
Karnofsky status % 90 (80-100) 
Prescribed dose 67Gy (range 66-70) 
D Mean 18 Gy (range 10-26) 
D max 38Gy (range 32-52) 
Volume 96.44cc (range 49-154) 
V20 Gy OC 48% 
V25Gy OC 26% 
V30 Gy OC 7% 
V35 Gy OC 1.5% 
V40 Gy OC 0.44% 
V45 Gy OC 0.16% 
V50Gy OC 0.010% 
Mucositis groups 
A 
B 
15 (78%) 
4 (21%) 
 
Table 1 Clinical and dosimetric results for the OC contour as 
OAR.  
 
Conclusions: This descriptive study shows contouring the OC 
in a tighter way can be achieved without risking PTV dose 
prescribe, the D mean and D max. Also features lesser D max 
D mean in the OC comparing the publications available, 
reaching more restrictive constrains dose and lowering sever 
mucositis presentation. More research is needed to compare 
different methods to contour the oral cavity to obtain a 
lower mucositis profile. 
   
 
 
 
